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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of antibiotics for the secondary prevention of coronary heart disease.
As a secondary objective, we plan to assess the effects of individual types of antibiotics for the secondary prevention of coronary heart
disease.
B A C K G R O U N D
Description of the condition
Coronary heart disease is the collective term for a group of dis-
eases consisting of stable angina, unstable angina, myocardial in-
farction, and sudden cardiac death (Wong 2014). Coronary heart
disease is estimated to be the leading cause of death worldwide
(WHO 2011; WHO 2016), and 15.5 million people in the USA
alone suffer from coronary heart disease (Mozaffarian 2016). The
World Health Organization (WHO) has estimated that 7.4 mil-
lion people die each year globally because of coronary heart dis-
ease with over three quarters of the deaths occurring in low- and
middle-income countries (WHO 2011; WHO 2016). Coronary
heart disease also has a significant impact on healthcare costs and
accounts for approximately EUR 196 billion in Europe and USD
207.3 billion in the USA (Ferreira-Gonzalez 2014; Mozaffarian
2016).
The pathogenesis of coronary heart disease is related to the nar-
rowing or blockage of the coronary arteries supplying the heart
with blood. This process is usually caused by build-up of fatty
material and plaque in the walls of the coronary arteries leading
to atherosclerosis (Ross 1999; Libby 2010; Libby 2011; Ambrose
2015). Atherosclerosis is a chronic immune-mediated inflamma-
tory disease that usually develops over years, ultimately limiting
perfusion to the heart, which may cause shortages of oxygen and
glucose, leading to symptoms such as chest pain (angina) and
shortness of breath (Ross 1999; Ambrose 2015).
People with established coronary heart disease have a high risk of
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subsequent cardiovascular events including cardiovascular death,
myocardial infarction, and stroke (Smith 2011;WHO2011; Eckel
2014; Piepoli 2016). Therapeutic lifestyle changes (e.g. increased
physical activity; weight reduction; dietary modification; smok-
ing cessation; and alcohol intake reduction) and adjunctive drug
therapies (e.g. antithrombotic treatment; managing hypertension;
diabetes; dyslipidaemia; and chronic kidney disease) are neces-
sary to improve survival and quality of life, and reduce recurrent
events and the need for revascularisation procedures (Smith 2011;
WHO 2011; Eckel 2014; Piepoli 2016). Nonetheless, even com-
plete adherence to the before-mentioned therapies is reported to
not completely eliminate the person’s risk of subsequent cardio-
vascular events (Bertrand 2016). This residual risk may result, in
part, from the failure of current therapies to efficiently address
inflammation (Bertrand 2016).
Studies have shown that inflammation seems to be a predictor
for the development and progression of atherosclerosis (Libby
2002; Kaptoge 2010; Lawson 2016) and the inflammatory process
may be induced by stimuli from infectious agents (Mendall 1996;
Rosenfeld 2011; Lawson 2016). The infectious agents might in-
duce the inflammatory process by infecting vascular cells within
the atheromatous plaque and consequently activating an innate
immune response (Rosenfeld 2011). The activated innate immune
response then contributes to the inflammation within the plaque
(Rosenfeld 2011). Moreover, infectious agents may induce in-
flammation at non-vascular places, which might lead to increased
secretion of cytokines and other acute-phase proteins. The cy-
tokines and other acute-phase proteins then add to the inflamma-
tion within the plaque (Rosenfeld 2011). Hence, an association
between coronary heart disease and various infectious agents has
been suggested and a number of studies have investigated the va-
lidity of this possible association.
Chlamydia pneumoniae has been identified in atheromatous
plaques (Shor 1992; Kuo 1993; Muhlestein 1996; Assar 2015;
Pigarevskii 2015). Moreover, seroepidemiological studies (Saikku
1988; Thom 1991; Linnanmaki 1993; Kazar 2005; Romano
Carratelli 2006; Sakurai-Komada 2014) and a meta-analysis of
seroepidemiological studies (Danesh 1997) have all shown in-
creased levels of C pneumoniae antibodies in people with coro-
nary heart disease. In vivo studies and a meta-analysis of ob-
servational studies have shown that C pneumoniae may con-
tribute to atherosclerosis (Burnett 2001; Ezzahiri 2002; Ezzahiri
2003; Filardo 2015). Contrary to these findings, prospective
seroepidemiological studies (Ridker 1999;Danesh 2000a; Danesh
2000b; Danesh 2002), retrospective seroepidemiological studies
(Prasad 2002; Al-Younes 2016), andmeta-analyses of seroepidemi-
ological studies (Danesh 2000a; Danesh 2000b; Danesh 2002;
Bloemenkamp 2003) did not show any association between C
pneumoniae antibodies and coronary heart disease.
Porphyromonas gingivalis has also been identified in atheroma-
tous plaques (Pucar 2007; Zaremba 2007; Gaetti-Jardim 2009;
Mahendra 2009). Moreover, studies have shown increased lev-
els of antibodies or higher amount of oral bacterial burden of P
gingivalis in people with coronary heart disease (Pussinen 2004;
Renvert 2006; Gotsman 2007; Mahendra 2015). In vivo stud-
ies have shown that P gingivalismay contribute to atherosclerosis
(Brodala 2005; Maekawa 2011). Contrary to these findings, ret-
rospective studies (Spahr 2006; Pesonen 2009; Andriankaja 2011)
and a prospective study (De Boer 2014) did not show any associ-
ation between P gingivalis and coronary heart disease.
Helicobacter pylori is another infectious agent that might induce an
inflammatory process and lead to coronary heart disease. The as-
sociation between coronary heart disease andH pylori has been as-
sessed in seroepidemiological studies (Mendall 1994; Lenzi 2006;
Vcev 2007; Shmuely 2014; Matusiak 2016), a meta-analysis of
seroepidemiological studies (Danesh 1997), and meta-analyses of
prospective studies (Sun 2016; Jiang 2017). These studies have
shown that infection with H pylori increases the risk of coro-
nary heart disease. Contrary to these findings, prospective studies
(Whincup 1996; Folsom 1998; Roivainen 2000; Zhu 2001; Zhu
2002; Jin 2007) and a meta-analysis of seroepidemiological stud-
ies (Danesh 1998) did not show any association between H pylori
and coronary heart disease.
A possible association between Escherichia coli and cardiovascular
disease has been assessed. However, a cohort study has shown that
infection with E coli did not increase the risk of cardiovascular dis-
ease in the decade following infection (Hizo-Abes 2013). Further,
a seroepidemiological study did not show any association between
E coli and coronary heart disease (Mahdi 2002).
Description of the intervention
Antibiotics are antimicrobial drugs of chemical origin that treat
and prevent bacterial infections by either killing or inhibiting the
growth of the bacteria (Waksman 1947). Antibiotics can be clas-
sified based on their mechanism of action (bactericidal or bac-
teriostatic), bacterial spectrum (broad or narrow) and chemical
structure (e.g. penicillins,macrolides, quinolones, or tetracyclines)
(Berdy 2005). The optimal dose and duration of antibiotic ther-
apy depends on various factors (e.g. the patient’s immune status,
the infecting agent, and the focus of infection) (Polk 1999).
Macrolides, such as azithromycin, clarithromycin, and ery-
thromycin, have been the primary antibiotic class used to inves-
tigate the effects of antibiotics as secondary prevention in people
with coronary heart disease, presumably because C pneumoniae
and H pylori are known to be sensitive to macrolides (Chirgwin
1989;Malfertheiner 2007). Macrolides’ mechanism of action is to
inhibit the protein synthesis through binding to the 50S subunit of
the ribosome (Gaynor 2003). However, the use of macrolides has
been reported in both observational studies and in a randomised
clinical trial to increase the risk of cardiovascular morbidity and
mortality (see Why it is important to do this review). The in-
creased risk of cardiovascular morbidity and mortality might be
associated with macrolides’ pro-arrhythmic effects (i.e. QT pro-
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longation) leading to torsades de pointes (Bril 2010). Further, the
use of macrolides might lead to an inflammatory cascade result-
ing in more vulnerable plaques that over time increases the risk of
plaque rupture and, hence, leads to increased risk of cardiovascular
events and mortality (Winkel 2011).
How the intervention might work
Antibiotics might prevent the development of coronary heart dis-
ease through antibacterial activity. In addition, animal studies
and in-vitro studies suggest that several classes of antibiotics (e.g.
macrolides, tetracyclines, or quinolones) seem to exert anti-in-
flammatory and anti-oxidative effects, which might slow down the
atherogenesis independently of any antibacterial effect (Anderson
1996; Rajagopalan 1996; Dalhoff 2003; Sapadin 2006; Steel
2012). The anti-inflammatory and anti-oxidative effects might
stabilise the atherosclerotic plaques.
Why it is important to do this review
Coronary heart disease is the leading cause of death worldwide as it
leads to 7.4 million deaths each year (WHO 2011; WHO 2016).
People with established coronary heart disease have a high risk of
subsequent cardiovascular events including cardiovascular death,
myocardial infarction, and stroke (Smith 2011;WHO2011; Eckel
2014; Piepoli 2016). Prevention and management of the common
risk factors for coronary heart disease is necessary to improve sur-
vival and quality of life, and reduce recurrent events and the need
for revascularisation procedures (Smith 2011; WHO 2011; Eckel
2014; Piepoli 2016). Nonetheless, even complete adherence to
the before-mentioned therapies may not completely eliminate the
person’s risk of subsequent cardiovascular events (Bertrand 2016).
The use of antibiotics might play a possible part in the preventive
efforts of people with coronary heart disease, and might improve
survival and quality of life, and reduce recurrent events and the
need for revascularisation procedures.
The use of antibiotics for secondary prevention of coronary heart
disease is not mentioned in any guidelines, indicating that it is not
conventional therapy (Fihn 2012; Montalescot 2013). However,
a very large number of people with coronary heart disease receive
antibiotics each year to treat proven or suspected bacterial infec-
tions. In the first instance, the antibiotics may help them. In the
second instance, any adverse event may be as likely as any bene-
fits. In both instances, we need to know the impact of antibiotic
intervention on long-term health.
The first trials that investigated the use of antibiotics for secondary
prevention of coronary heart disease were published in the late
1990s. The trials compared macrolide versus placebo in people
with coronary heart disease. The trials showed conflicting results
and made clear the need for larger trials (Gupta 1997; Anderson
1999; Torgano 1999; Gurfinkel 1999).
Several meta-analyses of randomised trials have assessed the ef-
fects of antibiotics for secondary prevention of coronary heart dis-
ease (Etminan 2004; Andraws 2005; Baker 2007; Gluud 2008).
Etminan 2004 included nine trials with 12,032 participants;
Andraws 2005 included 11 trials with 19,217 participants; and
Baker 2007 included six trialswith 13,778participants. All of these
reviews compared antibiotics versus placebo. None of the reviews
showed any benefits or harms of antibiotic therapy for secondary
prevention of coronary heart disease. Gluud 2008 included 17 tri-
als with 25,271 participants comparing antibiotics versus placebo,
and found a significantly increased risk of all-cause mortality of
10% in the antibiotic group. Moreover, Gluud 2008 did a meta-
analysis of the three trials that reported more than two years’ fol-
low-up (i.e. PROVE-IT (Cannon 2005), ACES (Grayston 2005),
and CLARICOR (Gluud 2008)) and showed a significantly in-
creased risk of all-cause mortality of 17% in the antibiotic group.
Cheng 2015 recently included 33 studies of various designs with
20,779,963 participants in a review comparing macrolides with
or to placebo or no intervention. The review included any type
of participant and did not focus on a specific infectious agent
or disease. The authors of the review found no significant effect
of macrolides on all-cause mortality. However, the participants
treated with macrolide had a significantly (152%) higher risk of
sudden death from cardiac problems and 31% had a higher risk
of dying from cardiovascular problems.
Currently, no guidelines report whether antibiotics should be used
or avoided as secondary prevention of coronary heart disease (Fihn
2012; Montalescot 2013). This might be because the use of an-
tibiotic therapy for secondary prevention of coronary heart disease
lost momentum a decade ago, possibly as a consequence of the
majority of previous evidence showing no effects - either benefi-
cial or harmful. Nevertheless, the public-health aspect of admin-
istration of antibiotics to people with coronary heart disease is
not to be neglected. Further, our preliminary literature search has
identified several new trials that were not included in the former
attempts to systematically review the literature, and more trials
may be identified during the literature search. Accordingly, the
benefits and harms of antibiotics in people with coronary heart
disease seem unclear based on current evidence. Furthermore, an-
tibiotics, including macrolide, are commonly used interventions
in people with coronary heart disease and any beneficial or harm-
ful effects of administering antibiotics in this group of people is
of urgent importance. The CLARICOR trial, as mentioned pre-
viously, showed that clarithromycin versus placebo for secondary
prevention of coronary heart disease significantly increased the risk
of death (Jespersen 2006; Gluud 2008; Winkel 2015). We, there-
fore, find it very important to investigate whether antibiotics have
a beneficial, neutral, or harmful effect for secondary prevention of
coronary heart disease.
No former relevant review has taken into account both risks of
random errors and risk of systematic errors (Cochrane method-
ology, Trial Sequential Analysis (TSA), and GRADE assessment)
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(Wetterslev 2008; Keus 2010; Higgins 2011a; Jakobsen 2014).
Therefore, it is still unclear whether antibiotics have a beneficial,
neutral, or harmful effect for secondary prevention of coronary
heart disease.
O B J E C T I V E S
To assess the beneficial and harmful effects of antibiotics for the
secondary prevention of coronary heart disease.
As a secondary objective, we plan to assess the effects of individual
types of antibiotics for the secondary prevention of coronary heart
disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials irrespective of trial design, setting,
blinding, publication status, publication year, and language. We
will not include quasi-randomised trials and observational studies
for the assessment of harms. By focusing on randomised clinical
trials, we are aware that the present review will be biased towards
focusing on more benefits and less on harms.
Types of participants
Participants with any diagnosis of coronary heart disease, that is,
acute myocardial infarction, previous myocardial infarction, stable
angina, or unstable angina. We will accept the definitions used by
the individual trialists. We will include participants irrespective of
age, sex, and antibody status (e.g. for C pneumoniae, H pylori, P
gingivalis, or E coli). We will exclude participants with any other
cause of chronic inflammatory disease (e.g. lupus erythematosus,
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis,
polymyositis/dermatomyositis, and inflammatory bowel disease).
We will only include trials that include a subset of eligible partic-
ipants if separate data for the eligible participants are available or
if the majority of participants (i.e. more than 80%) are eligible.
We will document difficult decisions in the review, and sensitivity
analyses will assess the impact of these decisions on the review’s
findings.
Types of interventions
We will include three types of comparisons:
• antibiotic compared with placebo;
• antibiotic compared with no intervention (including no
placebo tablet); and
• antibiotic added to a co-intervention compared with a
similar co-intervention.
We will accept any type of antibiotic (e.g. azithromycin, clar-
ithromycin, erythromycin, doxycycline, tetracycline hydrochlo-
ride, gatifloxacin, levofloxacin, moxifloxacin, telithromycin, peni-
cillin, amoxicillin, or metronidazole) as the experimental inter-
vention, irrespective of dose, route of administration, or duration.
We will assess the effects of the individual types of antibiotics in
subgroup analyses.
We will accept any type of co-intervention when such co-inter-
vention is intended to be delivered similarly to the experimental
and the control group. We will assume that the effects of the co-
interventions will ’even out’ in both groups so that the possible
effects of the antibiotic will be reflected in the results. We will
do a check of co-interventions after randomisation in both inter-
vention groups and consider any major differences in our con-
clusions. As optimal medical therapy plays an important role for
the secondary prevention of coronary heart disease, we will per-
form a sensitivity analysis excluding trials with sub-optimal med-
ical therapy. Optimal medical therapy indicates at least one drug
for angina/ischaemic relief (e.g. short-acting nitrates, beta block-
ers, and calcium channel blockers) plus drugs for event prevention
(e.g. aspirin, clopidogrel, statins, ACE inhibitors, and angiotensin
receptor blockers) (Montalescot 2013).
Types of outcome measures
For all outcomes we will use the trial results at maximal follow-
up. However, if the trialists report results at multiple time points,
we will also assess the results reported at the time point closest to
24 months (plus and minus six months).
We chose 24 months’ follow-up based on the Kaplan-Meier curve
made by Winkel 2015. We believe that 24 months’ follow-up is
long enough to show any possible secondary prevention effects
of antibiotics. Furthermore, 24 months’ follow-up is not so long
that other factors, unrelated to the given trial but affecting the
outcomes, might decrease the statistical power, that is, that the
results are ’diluted’ by events unrelated to the trial.
Primary outcomes
• All-cause mortality
• Serious adverse event. We will define a serious adverse event
as any untoward medical occurrence that resulted in death; was
life-threatening; required hospitalisation or prolongation of
existing hospitalisation; resulted in persistent or significant
disability; or jeopardised the patient (ICH-GCP 1997).
4Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Quality of life measured on any valid scale
Secondary outcomes





• Sudden cardiac death
We will include randomised clinical trials irrespective of whether
they report the above outcomes.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, LILACS, Science Citation
Index Expanded on Web of Science and BIOSIS in order to iden-
tify relevant trials. The preliminary search strategy for MEDLINE
(Ovid) is given in Appendix 1 and will be adapted for use in the
other databases. We will apply the Cochrane sensitivity-maximis-
ing randomised clinical trial filter (Lefebvre 2011) to MEDLINE
(Ovid) and adaptations of it to the other databases, except CEN-
TRAL.
We will search all databases from their inception to the present
and we will impose no restriction on language of publication or
publication status. We will assess non-English language papers by
asking individuals that fluently speak the language for help. We
will not perform a separate search for adverse effects of antibiotics
used for the treatment of coronary heart disease. We will only
consider adverse effects described in the included trials.
Searching other resources
The reference lists of included randomised clinical trials, previous
systematic reviews, and other kinds of reviews will be checked for
any unidentified randomised clinical trials.Wewill contact authors
of included randomised clinical trials for further information and
we will contact the following major pharmaceutical companies by
email asking them for any unpublished randomised clinical trials:
• Merck & Co.;





• Bristol-Myers Squibb Co.;
• Sanofi-Aventis;
• Abbott Laboratories;
• Taisho Pharmaceutical; and
• Pliva.
Furthermore, we will search for ongoing and unidentified ran-
domised clinical trials on:
• Google Scholar;
• The Turning Research into Practive (TRIP) Database;
• ClinicalTrials.gov;
• EU Clinical Trial Register;
• Chinese Clinical Trial Registry (ChCTR);
• International Standard Randomised Controlled Trial
Number (ISRCTN) registry;
• GSK Clinical Study Register;
• Pan African Clinical Trials Registry (PACTR);
• Australian New Zealand Clinical Trials Registry
(ANZCTR);
• Clinical Trials Registry - India (CTRI); and
• the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal.
We will also examine relevant retraction statements and errata for
included trials.
Data collection and analysis
We will follow Cochrane recommendations to perform the review
(Higgins 2011a) and we will use Review Manager 5 (RevMan 5)
to perform the analyses (RevMan 2014) and TSA (TSA 2011).
Selection of studies
Two authors (NJS, SS) will independently screen titles and ab-
stracts. We will retrieve all relevant full-text study reports/publica-
tions and two review authors (NJS, SS) will independently screen
the full text and identify and record reasons for exclusion of the
ineligible studies. We will resolve disagreements through discus-
sion or, if required, by consulting with a third author (JCJ). We
will display trial selection in a flow diagram as per the PRISMA
statement (Moher 2009).
We will record the selection process in sufficient detail to complete
a PRISMA flow diagram and ’Characteristics of excluded studies’
table.
Data extraction and management
Three authors (NJS, SS, SKK) will extract data independently
from included trials. We will resolve any disagreements by discus-
sion with a fourth author (JCJ). We will assess duplicate publica-
tions and companion papers of a trial together in order to eval-
uate all available data simultaneously (maximise data extraction,
correct bias assessment). We will contact the authors of the trials
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by email to specify any of the data, had they not been reported
sufficiently in the publication.
Trial characteristics
Bias risk components (as defined below); trial design (parallel, fac-
torial, or cross-over); number of intervention arms; length of fol-
low-up; estimation of sample size; inclusion and exclusion criteria.
Participant characteristics and diagnosis
Number of randomised participants; number of analysed partici-
pants; number of participants lost to follow-up/withdrawals/cross
over; age range (mean or median) and sex ratio; presence of cardio-
vascular risk factors (i.e. diabetes mellitus, hypertension, hyperlip-
idaemia, or smoking); antibody status (i.e. for C pneumoniae, H
pylori, P gingivalis, or E coli).
Intervention characteristics
Type of antibiotic; dose of antibiotic; duration of antibiotic ther-




Type of co-intervention; dose of co-intervention; duration of co-
intervention; and mode of administration.
Outcomes
We will extract all outcomes listed above from each randomised
clinical trial, andwewill identifywhether outcomes are incomplete
or selectively reported according to the criteria described in Table
1.
Notes
We will extract details on funding of the trial and notable conflicts
of interest of trial authors, if available.
We will note in the ’Characteristics of included studies’ table if
outcome data were not reported in a usable way. Two review au-
thors (NJS, SS) will independently transfer data into the RevMan
5 file (RevMan 2014). We will resolve any disagreements through
discussion or, if required, by consulting a third author (JCJ).
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2017) in our evalua-
tion of the methodology and hence the risk of bias of the included
trials. We will evaluate the methodology in respect of:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other risks of bias;
• overall risk of bias.
These domains enable classification of randomised trials with low
risk of bias and high risk of bias. The latter trials tend to overes-
timate positive intervention effects (benefits) and underestimate
negative effects (harms) (Schulz 1995; Moher 1998; Kjaergard
2001; Gluud 2006; Wood 2008; Savovic 2012; Lundh 2017).
We will classify the trials according to the criteria described in
Table 1.
We will assess the domains ’blinding of outcome assessment’, ’in-
complete outcome data’, and ’selective outcome reporting’ for each
outcome result. Thus, we will be able to assess the bias risk for
each outcome assessed in addition to each trial.
Assesment of bias in conducting the systematic review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
Dichotomous outcomes
We will calculate risk ratios (RRs) with 95% confidence interval
(CI) for dichotomous outcomes, as well as the TSA-adjusted CIs
(see below).
Continuous outcomes
Wewill calculate themean differences (MDs) and the standardised
mean difference (SMD) with 95% CI for continuous outcomes,
as well as the TSA-adjusted CIs (see below).
Wewill consider using the SMDapproach when all the trials assess
the same outcome but measure it in a variety of ways, but only as
a hypothesis-generating analysis (Deeks 2017).
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Unit of analysis issues
We will only include randomised clinical trials. For trials using
cross-over design, we will only include data from the first period
(Elbourne 2002; Deeks 2017). There will, therefore, not be any
unit of analysis issues.
Dealing with missing data
Wewill, as a first option, contact all trial authors to obtain missing
data (i.e. for data extraction and for assessment of risk of bias, as
specified above).
Dichotomous outcomes
Wewill not imputemissing values for any outcomes in our primary
analysis. In two of our sensitivity analyses (see paragraph below),
we will impute data.
Continuous outcomes
We will primarily analyse scores assessed at single time points. If
only change from baseline scores are reported, we will analyse the
results together with follow-up scores (Higgins 2011b). If standard
deviations (SDs) are not reported, we will calculate the SDs using
trial data if possible. We will not use intention-to-treat data if the
original report did not contain such data. We will not impute
missing values for any outcomes in our primary analysis. In two
of our sensitivity analyses (see paragraph below), we will impute
data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually assess any sign
of heterogeneity. We will secondly assess the presence of statisti-
cal heterogeneity by Chi2 test (threshold P < 0.10) and measure
the quantities of heterogeneity by the I2 statistic (Higgins 2002;
Higgins 2003).
Wewill follow the recommendations for thresholds in theCochrane
Handbook for Systematic Reviews of Interventions (Deeks 2017):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90% may represent substantial heterogeneity;
• 75% to 100%: may represent considerable heterogeneity.
We will investigate possible heterogeneity through subgroup anal-
yses. Ultimately, we may decide that a meta-analysis should be
avoided (Deeks 2017).
Assessment of reporting biases
Wewill use a funnel plot to assess reporting bias if we include 10 or
more trials.Wewill visually inspect funnel plots to assess the risk of
bias. We are aware of the limitations of a funnel plot (i.e. a funnel
plot assesses bias due to small sample size. From this information,
we will assess possible reporting bias). For dichotomous outcomes,
we will test asymmetry with the Harbord test (Harbord 2006).
For continuous outcomes, we will use the regression asymmetry
test (Egger 1997) and the adjusted rank correlation (Begg 1994).
Data synthesis
Meta-analysis
We will undertake this meta-analysis according to the recommen-
dations stated in the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2017), by Keus and colleagues (Keus 2010),
and according to the eight-step assessment suggested by Jakobsen
and colleagues (Jakobsen 2014). We will use the Cochrane statis-
tical software RevMan 5 (RevMan 2014) to analyse data.
We will assess our intervention effects with both random-effects
meta-analyses (DerSimonian 1986) and fixed-effect meta-analy-
ses (DeMets 1987). We will use the more conservative point es-
timate of the two (Jakobsen 2014). The more conservative point
estimate is the estimate closest to zero effect. If the two estimates
are similar, we will use the estimate with the widest CI. We will
conduct sensitivity analyses and subgroup analyses to explore the
reasons for substantial statistical heterogeneity (see Assessment of
heterogeneity). We will assess the risk of publication bias in meta-
analyses consisting of 10 trials or more by visual inspection of
funnel plots and statistical tests for funnel plot asymmetry (see
Assessment of reporting biases). We will adjust our thresholds for
statistical significance when there are problems with multiplic-
ity (family-wise error rate), by dividing the pre-specified P value
threshold with the value halfway between 1 (no adjustment) and
the number of primary or secondary outcome comparisons (Bon-
ferroni adjustment) (Jakobsen 2014; Jakobsen 2016). There are
three primary outcomes in this review, therefore, we will consider
a P value of 0.025 or less as the threshold for statistical significance
for these outcomes (Jakobsen 2014), and there are four secondary
outcomes, therefore, wewill consider a P value of 0.02 or less as the
threshold for statistical significance for these outcomes (Jakobsen
2014; Jakobsen 2016). We will use the eight-step procedure to as-
sess whether the thresholds for significance are crossed (Jakobsen
2014). We will include all trials in our analyses and conduct a sen-
sitivity analysis excluding trials with high risk of bias. If the results
are similar, we will base our primary conclusions on the overall
analysis. If they differ, we will base our primary conclusions on
trials at low risk of bias.
Where multiple trial intervention groups are reported in a single
trial, we will include only the relevant groups. If two comparisons
are combined in the same meta-analysis, we will halve the control
group to avoid double-counting (Deeks 2017).
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Trial Sequential Analysis
Cumulative meta-analyses are at risk of producing random errors
due to sparse data and multiple testing of accumulating data (Brok
2008; Wetterslev 2008; Brok 2009; Thorlund 2009; Wetterslev
2009; Thorlund 2010; Thorlund 2011; TSA 2011; Imberger
2015; Imberger 2016; Wetterslev 2017), therefore, TSA (TSA
2011) can be applied to control these risks (www.ctu.dk/tsa/)
(Thorlund 2011). Similar to a sample size calculation in a ran-
domised clinical trial, TSA calculates the required information size
(that is, the number of participants needed in a meta-analysis to
detect or reject a certain intervention effect) in order to minimise
random errors (Wetterslev 2009). The required information size
takes into account the anticipated intervention effect, the variance
of the anticipated difference in intervention effects, the acceptable
risk of falsely rejecting the null hypothesis (alpha), the acceptable
risk of falsely confirming the null hypothesis (beta), and the vari-
ance of the intervention effect estimates between trials (Wetterslev
2009; Turner 2013; Jakobsen 2014). To determine and predefine
the anticipated intervention effects, we searched for suitable em-
pirical data (Jakobsen 2014). However, no suitable data could be
found. Instead, we pragmatically hypothesise the anticipated in-
tervention effects:
• When analysing dichotomous outcomes, we pragmatically
anticipate an intervention effect equal to a relative risk reduction
of 15%.
• When analysing continuous outcomes, we pragmatically
anticipate an intervention effect equal to the mean difference of
the observed SD/2 (Norman 2003).
TSA enables testing for significance to be conducted each time
a new trial is included in the meta-analysis. On the basis of the
required information size, trial sequential monitoring boundaries
are constructed. This enables one to determine the statistical infer-
ence concerning cumulative meta-analysis that has not yet reached
the diversity-adjusted required information size (Wetterslev 2008;
Wetterslev 2009).
Firm evidence for benefit or harm may be established if a trial
sequential monitoring boundary is crossed before reaching the di-
versity-adjusted required information size, in which case further
trials may turn out to be superfluous. In contrast, if a boundary
is not surpassed one may conclude that it is necessary to continue
with further trials before a certain intervention effect can be de-
tected or rejected. Firm evidence for lack of the postulated inter-
vention effect can also be assessed with TSA. This occurs when
the cumulative Z-score crosses the trial sequential boundaries for
futility.
For dichotomous outcomes, we will estimate the required infor-
mation size based on a relative risk reduction of 15%, the observed
proportion of participants with an outcome in the control group,
an alpha of 2.5% for our primary outcomes and 2.0% for our sec-
ondary outcomes (see ’Meta-analysis’ above), a beta of 10%, and
diversity as suggested by the trials in the meta-analysis (diversity-
adjusted required information size) (Wetterslev 2009; Jakobsen
2014). In case there is some evidence or effect of the intervention,
a supplementary TSA will use the limit of the CI closest to 1.00 as
the anticipated intervention effect (Jakobsen 2014). Additionally,
we will calculate TSA-adjusted CIs.
For continuous outcomes, we will estimate the required informa-
tion size based on a minimal clinically important difference of
SD/2, the standard deviation observed in the control group, an
alpha of 2.5% for our primary outcomes and 2.0% for our sec-
ondary outcomes (see ’Meta-analysis’ above), a beta of 10%, and a
diversity as suggested by the trials in the meta-analysis (diversity-
adjusted required information size) (Wetterslev 2009; Jakobsen
2014). In case there is some evidence of effect of the intervention,
a supplementary TSA will use the limit of the CI closest to 0.00 as
the anticipated intervention effect (Jakobsen 2014). Additionally,
we will calculate TSA-adjusted CIs.
Subgroup analysis and investigation of heterogeneity
We will perform the following subgroup analyses when assessing
each outcome (all-cause mortality, serious adverse event, quality
of life, cardiovascular mortality, myocardial infarction, stroke, and
sudden cardiac death) both at the time point closest to 24 months’
follow-up and at maximal follow-up.
• Comparison of the effects between trials with different
types of antibiotic (e.g. azithromycin, clarithromycin,
erythromycin, doxycycline, tetracycline hydrochloride,
gatifloxacin, levofloxacin, moxifloxacin, telithromycin,
penicillin, amoxicillin, or metronidazole).
• Antibody status (i.e. people with identified C pneumoniae,
H pylori, P gingivalis, orE coli antibodies compared to people
without any identified C pneumoniae, H pylori, P gingivalis, orE
coli antibodies).
• Comparison of participants on statins at entry compared to
participants not on statins at entry (Jensen 2010).
• Comparison of the mean age of participants (0 to 59 years,
60 to 79 years, 80 years and over).
• Comparison of the effects between trials with different
clinical trial registration status (pre-registration, post-registration
or no registration).
Additionally, we will perform the following subgroup analysis
when assessing each outcome (all-cause mortality, serious adverse
event, quality of life, cardiovascular mortality, myocardial infarc-
tion, stroke, and sudden cardiac death) at maximal follow-up.
• Comparison of trials with less than 12 months’ follow-up
with trials equal to or longer than 12 months’ follow-up.
We will use the formal test for subgroup differences in RevMan 5
(RevMan 2014).
Sensitivity analysis
To assess the potential impact of bias, we will perform a sensitivity
analysis in which we exclude trials at overall high risk of bias.
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To assess the potential impact of themissing data for dichotomous
outcomes, we will perform the following four sensitivity analyses
when assessing each dichotomous outcome (all-cause mortality,
serious adverse event, cardiovascular mortality, myocardial infarc-
tion, stroke, and sudden cardiac death).
• ’Best-worst-case’ scenario: we will assume that all
participants lost to follow-up in the experimental group have
survived, had no serious adverse event, had no cardiovascular
death, had no myocardial infarction, had no stroke, and had no
sudden cardiac death; and all those participants lost to follow-up
in the control group have not survived, had a serious adverse
event, had a cardiovascular death, had a myocardial infarction,
had a stroke, and had a sudden cardiac death.
• ’Worst-best-case’ scenario: we will assume that all
participants lost to follow-up in the experimental group have not
survived, had a serious adverse event, had a cardiovascular death,
had a myocardial infarction, had a stroke, and had a sudden
cardiac death; and that all those participants lost to follow-up in
the control group have survived, had no serious adverse event,
had no cardiovascular death, had no myocardial infarction, had
no stroke, and had no sudden cardiac death.
• A modified ’best-worst-case’ scenario: we will assume that
half of the participants lost to follow-up in the experimental
group have survived, had no serious adverse event, had no
cardiovascular death, had no myocardial infarction, had no
stroke, and had no sudden cardiac death; and that half of the
participants lost to follow-up in the control group have not
survived, had a serious adverse event, had a cardiovascular death,
had a myocardial infarction, had a stroke, and had a sudden
cardiac death.
• A modified ’worst-best-case’ scenario: we will assume that
half of the participants lost to follow-up in the experimental
group have not survived, had a serious adverse event, had a
cardiovascular death, had a myocardial infarction, had a stroke,
and had a sudden cardiac death; and that half of the participants
lost to follow-up in the control group have survived, had no
serious adverse event, had no cardiovascular death, had no
myocardial infarction, had no stroke, and had no sudden cardiac
death.
We will present results of all four scenarios in our review.
When analysing quality of life, a ‘beneficial outcome’ will be the
group mean plus two standard deviations (SDs) (we will then use
one SD in another sensitivity analysis) of the group mean, and a
‘harmful outcome’ will be the group mean minus two SDs (we
will then use one SD in another sensitivity analysis) of the group
mean (Jakobsen 2014).
To assess the potential impact of missing SDs for continuous out-
comes, we will perform the following sensitivity analysis.
• Where SDs are missing and it is not possible to calculate
them, we will impute SDs from trials with similar populations
and low risk of bias. If we find no such trials, we will impute SDs
from trials with a similar population. As the final option, we will
impute SDs from all trials.
We will present results of this scenario in our review.
Other post-hoc sensitivity analyses might be warranted if unex-
pected clinical or statistical heterogeneity is identified during the
analysis of the review results (Jakobsen 2014).
’Summary of Findings’ table
We will create a Summary of Findings table using each of the
primary (all-cause mortality, serious adverse event, and quality
of life) and secondary outcomes (cardiovascular mortality, my-
ocardial infarction, stroke, and sudden cardiac death). We will
use the five GRADE considerations (trial limitations, consistency
of effect, imprecision, indirectness, and publication bias) to as-
sess the quality of a body of evidence as it relates to the stud-
ies that contribute data to the meta-analyses for the prespeci-
fied outcomes (Schunemann 2003; Guyatt 2008; Guyatt 2011;
Jakobsen 2014). We will use methods and recommendations de-
scribed in chapter 8 (Section 8.5) (Higgins 2011b) and Chapter
12 (Schünemann 2017) of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a) using GRADEpro GDT
software (GRADEpro GDT 2015; Schunemann 2013). We will
justify all decisions to downgrade the quality of studies using foot-
notes and we will make comments to aid the reader’s understand-
ing of the review where necessary.
We will include all trials in our analyses, and conduct a sensitivity
analysis excluding trials at high risk of bias. If the results are similar,
wewill base our primary ’Summary of Findings’ tables andprimary
conclusions on the overall analysis. If they differ, we will base our
primary ’Summary of Findings’ tables and primary conclusions on
trials at low risk of bias.
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A D D I T I O N A L T A B L E S
Table 1. The Cochrane tool for assessing risk of bias
Domain Description
Random sequence generation • Low risk: if sequence generation was achieved using computer random number
generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice were also considered adequate if performed by an independent
adjudicator.
• Unclear risk: if the method of randomisation was not specified, but the trial was
still presented as being randomised.
• High risk: if the allocation sequence was not randomised or only quasi-
randomised. We will exclude these trials.
Allocation concealment • Low risk: if the allocation of participants was performed by a central independent
unit, on-site locked computer, identical-looking numbered sealed envelopes, drug
bottles, or containers prepared by an independent pharmacist or investigator.
• Uncertain risk: if the trial was classified as randomised but the allocation
concealment process was not described.
• High risk: if the allocation sequence was familiar to the investigators who assigned
participants.
Blinding of participants and personnel • Low risk: if the participants and the personnel were blinded to intervention
allocation and this was described.
• Uncertain risk: if the procedure of blinding was insufficiently described.
• High risk: if blinding of participants and the personnel was not performed.
Blinding of outcome assessment • Low risk of bias: if it was mentioned that outcome assessors were blinded and this
was described.
• Uncertain risk of bias: if it was not mentioned if the outcome assessors in the trial
were blinded, or the extent of blinding was insufficiently described.
• High risk of bias: if no blinding or incomplete blinding of outcome assessors was
performed.
Incomplete outcome data • Low risk of bias: if missing data were unlikely to make treatment effects depart
from plausible values. This could either be: 1) there were no drop-outs or withdrawals
for all outcomes, or 2) the numbers and reasons for the withdrawals and drop-outs for
all outcomes were clearly stated and could be described as being similar in both groups.
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Table 1. The Cochrane tool for assessing risk of bias (Continued)
Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if
drop-outs are less than 5%. However, the 5% cut-off is not definitive.
• Uncertain risk of bias: if there was insufficient information to assess whether
missing data were likely to induce bias on the results.
• High risk of bias: if the results were likely to be biased due to missing data either
because the pattern of drop-outs could be described as being different in the two
intervention groups or the trial used improper methods in dealing with the missing
data (e.g. last observation carried forward).
Selective outcome reporting • Low risk of bias: if a protocol was published before or at the time the trial was
begun and the outcomes specified in the protocol were reported on. If there is no
protocol or the protocol was published after the trial has begun, reporting of all-cause
mortality and serious adverse events will grant the trial a grade of low risk of bias.
• Uncertain risk of bias: if no protocol was published and the outcomes all-cause
mortality and serious adverse events were not reported on.
• High risk of bias: if the outcomes in the protocol were not reported on.
Other risks of bias • Low risk of bias: if the trial appears to be free of other components (for example,
academic bias or for-profit bias) that could put it at risk of bias.
• Unclear risk of bias: if the trial may or may not be free of other components that
could put it at risk of bias.
• High risk of bias: if there are other factors in the trial that could put it at risk of
bias (for example, authors have conducted trials on the same topic, for-profit bias etc).
Overall risk of bias • Low risk of bias: the trial will be classified as overall ’low risk of bias’ only if all of
the bias domains described in the above paragraphs are classified as ’low risk of bias’.
• High risk of bias: the outcome result will be classified ’high risk of bias’ if any of the
bias risk domains described in the above are classified as ’unclear’ or ’high risk of bias’.
A P P E N D I C E S
Appendix 1. MEDLINE preliminary search strategy
1. exp Coronary Disease/
2. exp Myocardial Ischemia/
3. (myocard* adj3 infarct*).tw.
4. (coronary adj3 disease*).tw.
5. (myocard* adj3 ischemi*).tw.
6. (myocard* adj3 ischaem*).tw.
7. (ischemic adj3 heart).tw.
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33. (antibiotic* or anti-bacterial* or anti-infective*).tw.
34. or/13-33
35. 12 and 34
36. randomized controlled trial.pt.







44. 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. exp animals/ not humans.sh.
46. 44 not 45
47. 35 and 46
WH A T ’ S N E W
Date Event Description
12 July 2017 New citation required and major changes Authorship changedwith newauthor andnewcontact person.Themeth-
ods have been updated in line with more recent Collaboration guidelines
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